Relationships between neuroradiological and clinical features in apparently idiopathic hypopituitarism

Teresa Arrigo, Filippo De Luca, Mohamad Maghnie, Alfredo Blandino, Fortunato Lombardo, Maria F Messina, Malgorzata Wasniewska, Lucia Ghizzoni, and Mauro Bozzola

Institute of Pediatrics, University of Messina, Italy, Institute of Pediatrics, University of Pavia, Italy, and Institute of Pediatrics, University of Parma, Italy

(Correspondence should be addressed to F De Luca, Istituto di Clinica Pediatrica, Policlinico Universitario, 98100 Messina, Italy)

Abstract

In this study, perinatal history, postnatal auxological and clinical evolution and endocrine features were retrospectively evaluated in 49 children, adolescents and young adults with apparently idiopathic hypopituitarism. They were divided into two groups according to magnetic resonance images: 32 patients with isolated pituitary hypoplasia (group A) and 17 with pituitary stalk interruption syndrome (group B). The aim of the study was to assess whether these neuroradiological pictures are associated with specific endocrine and clinical patterns. No significant difference in terms of gestational age, intrauterine growth and rates of adverse perinatal events was found between the two groups. Clinical signs documenting the existence of pituitary dysfunction in utero or shortly after birth were either slightly (micropenis, cryptorchidism, cholestatic jaundice) or significantly (hypoglycemia) more frequent in patients in group B. Although diagnosis of hypopituitarism was made significantly earlier in patients in group B, height deficiency at diagnosis was similar in both groups. Endocrine investigations revealed a more severe and widespread impairment of pituitary function among those in group B. The main conclusion is that the postnatal clinical course is more severe when growth hormone deficiency is associated with pituitary stalk interruption syndrome than when the pituitary is only reduced in height, probably because of the more severe and widespread impairment of pituitary function in the former cases.

European Journal of Endocrinology 139 84–88

Introduction

Magnetic resonance imaging (MRI) is a non-invasive technique that facilitates good visualization of both the hypophysis and the pituitary stalk (1–4), thus improving our understanding of the pathophysiology of apparently idiopathic growth hormone deficiency (GHD) (5–8).

The most frequent defects observed by MRI in children with non-tumoral GHD are isolated pituitary hypoplasia and pituitary stalk interruption syndrome i.e. pituitary stalk interruption associated with anterior pituitary hypoplasia or no visible anterior lobe.

Pituitary stalk interruption syndrome seems to be more strongly associated with perinatal adverse events (9–10) and has been reported more frequently in patients with multiple pituitary hormone deficiency than in those with isolated GHD (6, 8, 9–12). Nevertheless, the existence of significant relationships between neuroradiological findings and either perinatal events or endocrine function in hypopituitarism has not been confirmed by others and the subject remains controversial (12–16).

In order to shed further light on the pathophysiology of apparently idiopathic GHD, we retrospectively evaluated perinatal history, postnatal clinical evolution and endocrine features in two groups of patients with non-tumoral and apparently idiopathic hypopituitarism and two different neuroradiological patterns, either isolated pituitary hypoplasia or pituitary stalk interruption syndrome.

Patients and methods

Our retrospective study involved 49 patients (35 males) with non-tumoral and apparently idiopathic GHD who were seen in our three clinics over the past 10 years and were diagnosed at a mean age of 5.6 ± 5.2 years (range 0.1–25.0 years) (9–10). All the patients admitted to the study fulfilled the following inclusion criteria: height < –2 SDS (standard deviation score) (mean –3.6 ± 1.3, range –2.1 to –7.1 SDS); growth hormone (GH) peak in response to at least two pharmacological stimulation tests (clonidine, insulin, arginine, L-dopa) < 10.0 μg/l (mean 3.0 ± 2.6, range 0.1–8.9 μg/l); presence of neuroradiological abnormalities such as isolated pituitary hypoplasia or pituitary stalk interruption, as demonstrated by MRI.

A tumoral cause of GHD was excluded by both clinical and neuroradiological evaluation. Many causes of
hereditary GHD were excluded on the basis of the following: absence of family history of hypopituitarism; non-consanguinity of patients’ parents; absence of known immunodeficiency or history of recurrent infections in GHD males; absence of GH antibodies in response to GH treatment; normal prolactin secretion in patients with both GH and thyrotropin (TSH) deficiency.

The patients were classified into two groups according to the MR images: group A, 32 patients (24 males) with isolated pituitary hypoplasia; group B, 17 patients (11 males) with pituitary stalk interruption, associated with pituitary hypoplasia in 12 or with no visible anterior pituitary lobe in the remaining five.

Patients’ perinatal history and their clinical, auxological and endocrine data were obtained from hospital records. Breech delivery and emergency cesarean section were considered to be abnormal deliveries. An Apgar score ≤7 at 5 min after birth was considered to be an indication of neonatal asphyxia. Abnormal deliveries and neonatal asphyxia were considered adverse perinatal events. The auxological data at birth, according to gestational age, were evaluated with respect to the standards of Usher & McLean (18), whereas the standards of Tanner & Whitehouse (19) were used to evaluate height at the time of diagnosis of the pituitary deficiency.

GH assays were performed in all cases using the same commercial kits based on polyclonal antibodies (Biodata, Milan, Italy). Thyroid and adrenal functions were evaluated in all patients, leading to a classification of isolated GHD or multiple pituitary hormone deficiency. The pituitary–thyroid axis function was investigated by evaluating serum thyroxine (T4), free T4, tri-iodothyronine (T3), free T3 and TSH baseline serum concentrations and by a TSH-releasing-hormone (TRH) test (200 μg/m2 i.v.): reduced free T4 values (<12 pmol/l) with a delayed TSH response after injection of TRH (TSH value at 60 min greater than that obtained at 20–30 min) was considered to indicate hypothalamic hypothyroidism.

Adrenal function was estimated as basal serum cortisol (normal values 265–365 nmol/l) and corticotropin (normal values 2.2–17.6 pmol/l) concentrations at 0800 h, and as the serum cortisol response to insulin-induced hypoglycemia (normal response was defined as an increase above baseline cortisol concentrations of more than 190 nmol/l or an increase to a peak value greater than 550 nmol/l). Diagnosis of gonadotropin deficiency was made on clinical grounds only in newborns with both microphallus and cryptorchidism; in other cases it was suggested by the absence of physical signs of pubertal development at advanced bone age (>12 years in girls and >13.5 years in boys) and confirmed by biochemical data (prepubertal baseline serum gonadotropin concentrations and no increase after injection of gonadotropin-releasing hormone 100 μg/m2 i.v.).

The MRI scan was routinely performed in all the patients included in our series before hormonal treat-
events were clearly more frequent than in the general population; in our three Hospitals, the average frequencies of abnormal deliveries (as previously defined) and neonatal asphyxia over the past 10 years were approximately 15% and 3% respectively. No significant difference in terms of gestational age and rates of adverse perinatal events was found between the two groups (Table 1).

Endocrine investigations revealed a more severe and widespread impairment of pituitary function in patients in group B, who exhibited both lower GH peaks after pharmacological stimulations and more frequent involvement of other pituitary hormones (Table 1). GH responses were very severely blunted (peak <3.0 µg/l) in many patients in both the groups (14 of 17 with pituitary stalk interruption syndrome, compared with 13 of 32 without the syndrome; χ² = 7.8, P < 0.01).

Both the average birth length and the prevalence of subnormal (<–2 SDS) birth length (6 of 17 compared with 6 of 32) were similar in the two groups, as were the patients’ heights at the time of diagnosis of their condition (Table 1). Diagnosis of GHD, however, was made significantly earlier in patients in group B (mean age at diagnosis 3.2 ± 2.3 years; range 0.1–10.0 years) than in those in group A (mean 6.9 ± 5.9; range 0.1–25.0 years; Table 1).

Clinical symptoms of the existence of pituitary dysfunction in utero or shortly after birth were observed in patients in both groups, although they were either slightly (genitalia abnormalities, cholestatic jaundice) or significantly (hypoglycemia) more frequent in those group B (Table 1).

Midline developmental defects were found in only two patients (one with cleft palate in group A and one with septo-optic dysplasia in group B).

**Discussion**

MRI is an additional and useful tool in the evaluation of patients with GHD, in whom a diagnosis of permanent hypopituitarism might be in doubt if both the anatomy and the height of the pituitary are normal (5, 21).

Patients were admitted to this study only if MRI revealed anterior pituitary hypoplasia. All were subsequently divided into two groups according to the presence or absence of pituitary stalk interruption. This study design enabled us to evaluate: a) the specific influences of pituitary stalk interruption syndrome on prenatal, perinatal and postnatal history of GHD patients; b) the relationships between pituitary stalk interruption syndrome and pituitary function; and c) whether GHD syndrome is characterized by different and peculiar endocrine and clinical patterns in the patients with either isolated pituitary hypoplasia or pituitary stalk interruption syndrome.

Pituitary failure began during intrauterine life in many infants with either isolated pituitary hypoplasia or pituitary stalk interruption syndrome, as suggested by the following perinatal data recorded in the patients of both groups: 1) the greater than normal frequency of infants with short birth length, which confirms that GH may have a role in prenatal growth (22, 23); 2) the pathological prevalence of both microphallus and bilateral cryptorchidism in boys; 3) the abnormally high frequency of adverse perinatal events, which might be regarded as a complication of prenatal hypopituitarism (23–27), at least in those patients with intrauterine growth retardation or intrauterine developmental defects.

Neither prenatal nor perinatal events were significantly affected by pituitary stalk interruption syndrome in patients with GHD – an observation that is in contrast with the findings of other studies (8, 24), but is strongly supported by the following: 1) pregnancy duration and rates of adverse perinatal events were similar in our patients both with or without pituitary stalk interruption syndrome; 2) length deficiency at birth was very similar in the two groups; 3) developmental defects of the genitalia were apparently more frequent in patients in group B, who exhibited both lower GH peaks after pharmacological stimulations and more frequent involvement of other pituitary hormones.

**Table 1** Perinatal, endocrine, auxological and clinical data of patients.

<table>
<thead>
<tr>
<th></th>
<th>Entire series (n = 49)</th>
<th>Group A (n = 32)</th>
<th>Group B (n = 17)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age (weeks)</td>
<td>39.5 ± 1.6</td>
<td>39.6 ± 1.4</td>
<td>39.2 ± 2.0</td>
<td>NS</td>
</tr>
<tr>
<td>Abnormal deliveries (%)</td>
<td>34.7</td>
<td>34.3</td>
<td>35.3</td>
<td>NS</td>
</tr>
<tr>
<td>Neonatal asphyxia (%)</td>
<td>26.5</td>
<td>28.1</td>
<td>23.5</td>
<td>NS</td>
</tr>
<tr>
<td>GH peaks (µg/l)</td>
<td>3.0 ± 2.6</td>
<td>3.8 ± 2.7</td>
<td>1.6 ± 1.7</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>MPHD (%)</td>
<td>36.7</td>
<td>21.9</td>
<td>64.7</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Birth length (SDS)</td>
<td>–1.3 ± 0.9</td>
<td>–1.3 ± 0.9</td>
<td>–1.4 ± 1.0</td>
<td>NS</td>
</tr>
<tr>
<td>Height at diagnosis (SDS)</td>
<td>–3.6 ± 1.2</td>
<td>–3.4 ± 1.1</td>
<td>–4.0 ± 1.5</td>
<td>NS</td>
</tr>
<tr>
<td>Age at diagnosis (years)</td>
<td>5.6 ± 5.2</td>
<td>6.9 ± 5.9</td>
<td>3.2 ± 2.3</td>
<td>&lt;0.0025</td>
</tr>
<tr>
<td>Microphallus (%)</td>
<td>20.0</td>
<td>12.5</td>
<td>36.4</td>
<td>NS</td>
</tr>
<tr>
<td>Cryptorchidism (%)</td>
<td>14.3</td>
<td>8.3</td>
<td>27.3</td>
<td>NS</td>
</tr>
<tr>
<td>Hypoglycemia (%)</td>
<td>14.3</td>
<td>3.1</td>
<td>35.3</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Cholestatic jaundice (%)</td>
<td>6.1</td>
<td>3.1</td>
<td>11.8</td>
<td>NS</td>
</tr>
</tbody>
</table>

MPHD, multiple pituitary hormone deficiency; NS, not significant.
stall interruption syndrome than in those with isolated pituitary hypoplasia, as has also been reported by others (5, 14, 28). GHD children with pituitary stalk interruption syndrome more frequently experienced hypoglycemic attacks, a complication observed in only a few who did not have the syndrome. In addition, cholestasis occurred slightly more frequently in patients with pituitary stalk interruption syndrome. Probably as a consequence of the more frequent postnatal clinical complications, diagnosis of hypopituitarism was made earlier in the patients with pituitary stalk interruption syndrome than in those in group A. In spite of the differences in age at diagnosis, height deficiency at the time of diagnosis was very similar in the two groups of subjects, which strongly suggests that growth velocity during the first years of life had been significantly lower in the children with pituitary stalk interruption syndrome than in those with isolated pituitary hypoplasia.

In our series, as in previous reports (1, 2, 5, 6, 8, 10, 12, 13, 15), pituitary function was more severely impaired in the patients with pituitary stalk interruption syndrome, as revealed by both the blunted GH responses to provocative tests and the frequent involvement of other pituitary hormones. In contrast, in the patients with isolated pituitary hypoplasia, GH secretion was less severely impaired and GHD was associated with other pituitary hormone deficiencies in only a few of them.

The major conclusion that can be drawn from the present study is that the postnatal clinical course is more severe when GHD is associated with pituitary stalk interruption syndrome than when the pituitary is only reduced in height, probably because of the more severe and widespread impairment of pituitary function in patients with pituitary stalk interruption syndrome.

Other significant inferences suggested by the analysis of our results are that, in GHD patients with subnormal pituitary height, hypopituitarism may start in utero, irrespective of whether pituitary hypoplasia is isolated or associated with other MRI abnormalities; that perinatal history is frequently similar in GHD patients with either isolated pituitary hypoplasia or pituitary stalk interruption syndrome; and that both isolated pituitary hypoplasia and pituitary stalk interruption syndrome may have a prenatal etiology in some patients.

References


Received 17 November 1997
Accepted 16 March 1998